Esperion Therapeutics has reached a settlement agreement with Hetero USA and its affiliates, resolving a patent litigation case concerning the generic version of NEXLETOL® (bempedoic acid). According to the agreement, Hetero USA will not market a generic version of NEXLETOL in the United States before April 19, 2040, unless specific conditions outlined in the agreement occur. Meanwhile, patent litigation with other defendants is ongoing, and it remains uncertain if a generic version of NEXLETOL or NEXLIZET will be available in the U.S. before the specified date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.